Cyclophosphamide Pill

DRUG3 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Kiromic BioPharma Inc., H. Lee Moffitt Cancer Center and Research Institute

Conditions

CancerPancreatic CancerProgressive Solid MalignanciesRefractory Solid MalignanciesRhabdomyosarcoma

Phase 1

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

TerminatedNCT02224599

Kiromic BioPharma Inc.Cancer, Progressive Solid Malignancies, Refractory Solid Malignancies

Start: 2017-07-28End: 2018-08-30Updated: 2020-04-24

Phase 2

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Active, not recruitingNCT01088789

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2010-04-20End: 2026-08-31Updated: 2025-08-26

Evolutionary Therapy for Rhabdomyosarcoma

Active, not recruitingNCT04388839

H. Lee Moffitt Cancer Center and Research InstituteRhabdomyosarcoma

Start: 2020-12-29End: 2027-08-31Updated: 2025-11-26

Related Papers

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer

BMJ Open2024-12-017 citations

Phase I/II study of BSK01, an artificial intelligence-driven, peptide-pulsed, mature DC immunotherapy for solid and hematological malignancies.

Journal of Clinical Oncology2018-05-201 citations

Phase I/II study of low-dose cyclophosphamide, tumor-associated peptide antigen-pulsed dendritic cell and low dose GM-CSF for solid and hematological tumors.

Journal of Clinical Oncology2018-02-101 citations